| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | high-affinity IgG receptor activity | 6.82e-07 | 2 | 17 | 2 | GO:0019771 | |
| GeneOntologyMolecularFunction | leukotriene receptor binding | 6.82e-07 | 2 | 17 | 2 | GO:0031774 | |
| GeneOntologyMolecularFunction | IgG receptor activity | 1.43e-05 | 7 | 17 | 2 | GO:0019770 | |
| GeneOntologyMolecularFunction | IgG binding | 3.74e-05 | 11 | 17 | 2 | GO:0019864 | |
| GeneOntologyMolecularFunction | immunoglobulin receptor activity | 6.17e-05 | 14 | 17 | 2 | GO:0019763 | |
| GeneOntologyMolecularFunction | immunoglobulin binding | 4.23e-04 | 36 | 17 | 2 | GO:0019865 | |
| GeneOntologyMolecularFunction | receptor tyrosine kinase binding | 2.61e-03 | 90 | 17 | 2 | GO:0030971 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 6.99e-03 | 149 | 17 | 2 | GO:1990782 | |
| GeneOntologyMolecularFunction | immune receptor activity | 8.51e-03 | 165 | 17 | 2 | GO:0140375 | |
| GeneOntologyBiologicalProcess | type III hypersensitivity | 6.38e-06 | 5 | 17 | 2 | GO:0001802 | |
| GeneOntologyBiologicalProcess | regulation of type III hypersensitivity | 6.38e-06 | 5 | 17 | 2 | GO:0001803 | |
| GeneOntologyBiologicalProcess | positive regulation of type III hypersensitivity | 6.38e-06 | 5 | 17 | 2 | GO:0001805 | |
| GeneOntologyBiologicalProcess | positive regulation of type II hypersensitivity | 2.87e-05 | 10 | 17 | 2 | GO:0002894 | |
| GeneOntologyBiologicalProcess | positive regulation of type IIa hypersensitivity | 2.87e-05 | 10 | 17 | 2 | GO:0001798 | |
| GeneOntologyBiologicalProcess | regulation of type II hypersensitivity | 3.50e-05 | 11 | 17 | 2 | GO:0002892 | |
| GeneOntologyBiologicalProcess | regulation of type IIa hypersensitivity | 3.50e-05 | 11 | 17 | 2 | GO:0001796 | |
| GeneOntologyBiologicalProcess | penetration of zona pellucida | 4.96e-05 | 13 | 17 | 2 | GO:0007341 | |
| GeneOntologyBiologicalProcess | antibody-dependent cellular cytotoxicity | 4.96e-05 | 13 | 17 | 2 | GO:0001788 | |
| GeneOntologyBiologicalProcess | positive regulation of hypersensitivity | 6.67e-05 | 15 | 17 | 2 | GO:0002885 | |
| GeneOntologyBiologicalProcess | type IIa hypersensitivity | 6.67e-05 | 15 | 17 | 2 | GO:0001794 | |
| GeneOntologyBiologicalProcess | type II hypersensitivity | 6.67e-05 | 15 | 17 | 2 | GO:0002445 | |
| GeneOntologyBiologicalProcess | positive regulation of acute inflammatory response to antigenic stimulus | 8.63e-05 | 17 | 17 | 2 | GO:0002866 | |
| GeneOntologyBiologicalProcess | positive regulation of phagocytosis, engulfment | 9.71e-05 | 18 | 17 | 2 | GO:0060100 | |
| GeneOntologyBiologicalProcess | positive regulation of membrane invagination | 9.71e-05 | 18 | 17 | 2 | GO:1905155 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen via MHC class I | 9.71e-05 | 18 | 17 | 2 | GO:0042590 | |
| GeneOntologyBiologicalProcess | regulation of hypersensitivity | 1.08e-04 | 19 | 17 | 2 | GO:0002883 | |
| GeneOntologyBiologicalProcess | positive regulation of inflammatory response to antigenic stimulus | 1.60e-04 | 23 | 17 | 2 | GO:0002863 | |
| GeneOntologyBiologicalProcess | regulation of phagocytosis, engulfment | 1.75e-04 | 24 | 17 | 2 | GO:0060099 | |
| GeneOntologyBiologicalProcess | regulation of membrane invagination | 1.90e-04 | 25 | 17 | 2 | GO:1905153 | |
| GeneOntologyBiologicalProcess | hypersensitivity | 1.90e-04 | 25 | 17 | 2 | GO:0002524 | |
| GeneOntologyBiologicalProcess | regulation of acute inflammatory response to antigenic stimulus | 2.22e-04 | 27 | 17 | 2 | GO:0002864 | |
| GeneOntologyBiologicalProcess | immune response-regulating cell surface receptor signaling pathway | 2.54e-04 | 393 | 17 | 4 | GO:0002768 | |
| GeneOntologyBiologicalProcess | positive regulation of myeloid leukocyte mediated immunity | 2.74e-04 | 30 | 17 | 2 | GO:0002888 | |
| GeneOntologyBiologicalProcess | Fc-gamma receptor signaling pathway | 4.65e-04 | 39 | 17 | 2 | GO:0038094 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen via MHC class I | 5.14e-04 | 41 | 17 | 2 | GO:0002474 | |
| GeneOntologyBiologicalProcess | positive regulation of acute inflammatory response | 5.40e-04 | 42 | 17 | 2 | GO:0002675 | |
| GeneOntologyBiologicalProcess | acute inflammatory response to antigenic stimulus | 5.40e-04 | 42 | 17 | 2 | GO:0002438 | |
| GeneOntologyBiologicalProcess | phagocytosis, recognition | 5.40e-04 | 42 | 17 | 2 | GO:0006910 | |
| GeneOntologyBiologicalProcess | retina development in camera-type eye | 6.46e-04 | 211 | 17 | 3 | GO:0060041 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen | 7.05e-04 | 48 | 17 | 2 | GO:0002478 | |
| GeneOntologyBiologicalProcess | regulation of T cell receptor signaling pathway | 9.25e-04 | 55 | 17 | 2 | GO:0050856 | |
| GeneOntologyBiologicalProcess | positive regulation of immunoglobulin mediated immune response | 9.59e-04 | 56 | 17 | 2 | GO:0002891 | |
| GeneOntologyBiologicalProcess | positive regulation of B cell mediated immunity | 9.59e-04 | 56 | 17 | 2 | GO:0002714 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous antigen | 1.03e-03 | 58 | 17 | 2 | GO:0019884 | |
| GeneOntologyBiologicalProcess | regulation of inflammatory response to antigenic stimulus | 1.14e-03 | 61 | 17 | 2 | GO:0002861 | |
| GeneOntologyBiologicalProcess | Fc receptor signaling pathway | 1.17e-03 | 62 | 17 | 2 | GO:0038093 | |
| GeneOntologyBiologicalProcess | immune response-regulating signaling pathway | 1.37e-03 | 615 | 17 | 4 | GO:0002764 | |
| GeneOntologyBiologicalProcess | regulation of acute inflammatory response | 1.37e-03 | 67 | 17 | 2 | GO:0002673 | |
| GeneOntologyBiologicalProcess | neuromuscular junction development | 1.41e-03 | 68 | 17 | 2 | GO:0007528 | |
| GeneOntologyBiologicalProcess | regulation of immune response | 1.45e-03 | 1085 | 17 | 5 | GO:0050776 | |
| GeneOntologyBiologicalProcess | phagocytosis, engulfment | 1.45e-03 | 69 | 17 | 2 | GO:0006911 | |
| GeneOntologyBiologicalProcess | negative regulation of TOR signaling | 1.67e-03 | 74 | 17 | 2 | GO:0032007 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen | 1.76e-03 | 76 | 17 | 2 | GO:0048002 | |
| GeneOntologyBiologicalProcess | regulation of antigen receptor-mediated signaling pathway | 1.80e-03 | 77 | 17 | 2 | GO:0050854 | |
| GeneOntologyBiologicalProcess | regulation of vesicle-mediated transport | 1.84e-03 | 667 | 17 | 4 | GO:0060627 | |
| GeneOntologyBiologicalProcess | plasma membrane invagination | 1.85e-03 | 78 | 17 | 2 | GO:0099024 | |
| GeneOntologyBiologicalProcess | regulation of immunoglobulin mediated immune response | 1.90e-03 | 79 | 17 | 2 | GO:0002889 | |
| GeneOntologyBiologicalProcess | regulation of B cell mediated immunity | 1.90e-03 | 79 | 17 | 2 | GO:0002712 | |
| GeneOntologyBiologicalProcess | regulation of myeloid leukocyte mediated immunity | 1.99e-03 | 81 | 17 | 2 | GO:0002886 | |
| GeneOntologyBiologicalProcess | membrane invagination | 2.30e-03 | 87 | 17 | 2 | GO:0010324 | |
| GeneOntologyBiologicalProcess | receptor-mediated endocytosis | 2.48e-03 | 337 | 17 | 3 | GO:0006898 | |
| GeneOntologyBiologicalProcess | positive regulation of immune system process | 2.64e-03 | 1242 | 17 | 5 | GO:0002684 | |
| GeneOntologyBiologicalProcess | positive regulation of phagocytosis | 2.96e-03 | 99 | 17 | 2 | GO:0050766 | |
| GeneOntologyBiologicalProcess | inflammatory response to antigenic stimulus | 3.20e-03 | 103 | 17 | 2 | GO:0002437 | |
| GeneOntologyBiologicalProcess | regulation of endocytosis | 3.72e-03 | 389 | 17 | 3 | GO:0030100 | |
| GeneOntologyBiologicalProcess | positive regulation of immune response | 4.34e-03 | 845 | 17 | 4 | GO:0050778 | |
| GeneOntologyBiologicalProcess | positive regulation of protein ubiquitination | 4.60e-03 | 124 | 17 | 2 | GO:0031398 | |
| GeneOntologyBiologicalProcess | camera-type eye development | 4.80e-03 | 426 | 17 | 3 | GO:0043010 | |
| GeneOntologyBiologicalProcess | cellular senescence | 4.89e-03 | 128 | 17 | 2 | GO:0090398 | |
| GeneOntologyBiologicalProcess | regulation of phagocytosis | 5.50e-03 | 136 | 17 | 2 | GO:0050764 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation | 5.74e-03 | 139 | 17 | 2 | GO:0019882 | |
| GeneOntologyBiologicalProcess | membrane organization | 5.74e-03 | 914 | 17 | 4 | GO:0061024 | |
| GeneOntologyCellularComponent | clathrin-coated endocytic vesicle membrane | 1.85e-03 | 79 | 17 | 2 | GO:0030669 | |
| GeneOntologyCellularComponent | clathrin-coated endocytic vesicle | 3.00e-03 | 101 | 17 | 2 | GO:0045334 | |
| GeneOntologyCellularComponent | neuromuscular junction | 3.67e-03 | 112 | 17 | 2 | GO:0031594 | |
| GeneOntologyCellularComponent | centriolar satellite | 4.76e-03 | 128 | 17 | 2 | GO:0034451 | |
| MousePheno | decreased susceptibility to autoimmune hemolytic anemia | 9.30e-06 | 5 | 14 | 2 | MP:0004828 | |
| MousePheno | abnormal macrophage antigen presentation | 4.17e-05 | 10 | 14 | 2 | MP:0002454 | |
| MousePheno | abnormal dendritic cell differentiation | 1.75e-04 | 20 | 14 | 2 | MP:0008115 | |
| Domain | Ig_2 | 1.97e-03 | 73 | 17 | 2 | PF13895 | |
| Domain | Galactose-bd-like | 3.24e-03 | 94 | 17 | 2 | IPR008979 | |
| Domain | Znf_RING/FYVE/PHD | 7.76e-03 | 459 | 17 | 3 | IPR013083 | |
| Domain | Immunoglobulin | 1.27e-02 | 190 | 17 | 2 | IPR013151 | |
| Domain | ig | 1.27e-02 | 190 | 17 | 2 | PF00047 | |
| Domain | Ig_sub2 | 1.89e-02 | 235 | 17 | 2 | IPR003598 | |
| Domain | EGF | 1.89e-02 | 235 | 17 | 2 | SM00181 | |
| Domain | IGc2 | 1.89e-02 | 235 | 17 | 2 | SM00408 | |
| Domain | EGF-like_dom | 2.11e-02 | 249 | 17 | 2 | IPR000742 | |
| Domain | EGF_1 | 2.21e-02 | 255 | 17 | 2 | PS00022 | |
| Domain | EGF-like_CS | 2.30e-02 | 261 | 17 | 2 | IPR013032 | |
| Domain | zf-C2H2 | 2.35e-02 | 693 | 17 | 3 | PF00096 | |
| Domain | EGF_2 | 2.37e-02 | 265 | 17 | 2 | PS01186 | |
| Pathway | REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION | 1.46e-04 | 343 | 12 | 4 | MM15712 | |
| Pathway | REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION | 2.19e-04 | 381 | 12 | 4 | M1066 | |
| Pathway | WP_MICROGLIA_PATHOGEN_PHAGOCYTOSIS_PATHWAY | 6.73e-04 | 46 | 12 | 2 | MM15837 | |
| Pathway | REACTOME_FCGR_ACTIVATION | 7.33e-04 | 48 | 12 | 2 | MM17214 | |
| Pathway | REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES | 7.33e-04 | 48 | 12 | 2 | MM14528 | |
| Pathway | REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES | 7.95e-04 | 50 | 12 | 2 | M510 | |
| Pathway | REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS | 9.97e-04 | 56 | 12 | 2 | MM14815 | |
| Pathway | REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION | 1.83e-03 | 76 | 12 | 2 | MM14526 | |
| Pathway | REACTOME_ADAPTIVE_IMMUNE_SYSTEM | 2.39e-03 | 719 | 12 | 4 | MM14540 | |
| Pathway | REACTOME_INTERFERON_GAMMA_SIGNALING | 3.02e-03 | 98 | 12 | 2 | M965 | |
| Pathway | REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION | 3.52e-03 | 106 | 12 | 2 | M518 | |
| Pathway | REACTOME_ADAPTIVE_IMMUNE_SYSTEM | 4.00e-03 | 828 | 12 | 4 | M1058 | |
| Pathway | REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS | 4.06e-03 | 114 | 12 | 2 | MM14814 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 28814603 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 15835266 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 18245810 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 8611682 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 16849450 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 8663283 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 16409296 | ||
| Pubmed | Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan. | 2.25e-07 | 2 | 17 | 2 | 37733444 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 28289219 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 25231998 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 30190171 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 8478020 | ||
| Pubmed | FcγR-binding affinity of monoclonal murine IgG1s carrying different N-linked Fc oligosaccharides. | 2.25e-07 | 2 | 17 | 2 | 31554601 | |
| Pubmed | Amelioration of Lupus Serum-Induced Skin Inflammation in CD64-Deficient Mice. | 2.25e-07 | 2 | 17 | 2 | 35273604 | |
| Pubmed | IgG3-mediated enhancement of the antibody response is normal in Fc gammaRI-deficient mice. | 2.25e-07 | 2 | 17 | 2 | 16305642 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 9257847 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 21124939 | ||
| Pubmed | Mouse FcgammaRI: identification and functional characterization of five new alleles. | 2.25e-07 | 2 | 17 | 2 | 10752630 | |
| Pubmed | Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. | 2.25e-07 | 2 | 17 | 2 | 24430180 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 38524127 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 30744065 | ||
| Pubmed | Serum anti-Fcgamma receptor autoantibodies in patients with alopecia areata. | 2.25e-07 | 2 | 17 | 2 | 17124586 | |
| Pubmed | Molecular cloning and expression of the mouse high affinity Fc receptor for IgG. | 2.25e-07 | 2 | 17 | 2 | 2136886 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 1830050 | ||
| Pubmed | FcRγ deficiency improves survival in experimental sepsis by down-regulating TLR4 signaling pathway. | 2.25e-07 | 2 | 17 | 2 | 30552619 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 31211699 | ||
| Pubmed | Sensory Neuron Expressed FcγRI Mediates Postinflammatory Arthritis Pain in Female Mice. | 2.25e-07 | 2 | 17 | 2 | 35833115 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 8077658 | ||
| Pubmed | Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity. | 2.25e-07 | 2 | 17 | 2 | 38885133 | |
| Pubmed | Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. | 2.25e-07 | 2 | 17 | 2 | 8480181 | |
| Pubmed | Differential gene expression modulated by the cytoplasmic domain of Fc gamma RIa (CD64) alpha-chain. | 2.25e-07 | 2 | 17 | 2 | 15528358 | |
| Pubmed | Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. | 2.25e-07 | 2 | 17 | 2 | 29576375 | |
| Pubmed | Functional characteristics of the high affinity IgG receptor, FcγRI. | 2.25e-07 | 2 | 17 | 2 | 21325219 | |
| Pubmed | Fc receptors and the common gamma-chain in experimental autoimmune encephalomyelitis. | 2.25e-07 | 2 | 17 | 2 | 14991835 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 1402657 | ||
| Pubmed | Novel Fc gamma receptor I family gene products in human mononuclear cells. | 2.25e-07 | 2 | 17 | 2 | 1430234 | |
| Pubmed | The involvement of FcR mechanisms in antibody-mediated rejection. | 2.25e-07 | 2 | 17 | 2 | 18049118 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 30636035 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 22003208 | ||
| Pubmed | Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. | 6.74e-07 | 3 | 17 | 2 | 16841095 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 19657115 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 12427132 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 26056254 | ||
| Pubmed | The essential role of complement in antibody-mediated resistance to Salmonella. | 6.74e-07 | 3 | 17 | 2 | 30179254 | |
| Pubmed | Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. | 6.74e-07 | 3 | 17 | 2 | 33032297 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 8697799 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 23728777 | ||
| Pubmed | MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I. | 6.74e-07 | 3 | 17 | 2 | 22287715 | |
| Pubmed | Tpl2 kinase regulates FcγR signaling and immune thrombocytopenia in mice. | 6.74e-07 | 3 | 17 | 2 | 23898046 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 9763663 | ||
| Pubmed | FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation. | 6.74e-07 | 3 | 17 | 2 | 22493081 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16543474 | ||
| Pubmed | C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes. | 6.74e-07 | 3 | 17 | 2 | 28432146 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 12594281 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 30297432 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 12875993 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 15880819 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 24161960 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 28924242 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 9892619 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 12707052 | ||
| Pubmed | Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. | 1.35e-06 | 4 | 17 | 2 | 16455953 | |
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 9551950 | ||
| Pubmed | Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. | 1.35e-06 | 4 | 17 | 2 | 12898452 | |
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 10770797 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 21169548 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 9171347 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 1379234 | ||
| Pubmed | Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway. | 1.35e-06 | 4 | 17 | 2 | 19996316 | |
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 12517949 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 12705859 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 16452176 | ||
| Pubmed | Evidence for Cd101 but not Fcgr1 as candidate for type 1 diabetes locus, Idd10. | 1.35e-06 | 4 | 17 | 2 | 15850792 | |
| Pubmed | The mouse Fc receptor for IgG (Ly-17): molecular cloning and specificity. | 1.35e-06 | 4 | 17 | 2 | 2957319 | |
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 12528127 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 28028748 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 31562320 | ||
| Pubmed | Dynamic macrophage "probing" is required for the efficient capture of phagocytic targets. | 1.35e-06 | 4 | 17 | 2 | 21135140 | |
| Pubmed | Fc receptor regulation of protective immunity against Chlamydia trachomatis. | 1.35e-06 | 4 | 17 | 2 | 11872097 | |
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 17182593 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 10760808 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 9490697 | ||
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 16517729 | ||
| Pubmed | Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. | 1.35e-06 | 4 | 17 | 2 | 16585547 | |
| Pubmed | Unveiling skin macrophage dynamics explains both tattoo persistence and strenuous removal. | 1.35e-06 | 4 | 17 | 2 | 29511065 | |
| Pubmed | 1.35e-06 | 4 | 17 | 2 | 15485887 | ||
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 17053192 | ||
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 2944118 | ||
| Pubmed | Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. | 2.25e-06 | 5 | 17 | 2 | 9653099 | |
| Pubmed | C-reactive protein binding to murine leukocytes requires Fc gamma receptors. | 2.25e-06 | 5 | 17 | 2 | 10640769 | |
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 19380812 | ||
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 1531670 | ||
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 9200458 | ||
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 27265505 | ||
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 28852207 | ||
| Pubmed | Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. | 2.25e-06 | 5 | 17 | 2 | 24401277 | |
| Pubmed | 2.25e-06 | 5 | 17 | 2 | 16520392 | ||
| Pubmed | Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII. | 2.25e-06 | 5 | 17 | 2 | 18354234 | |
| Pubmed | Role of FcRs in animal model of autoimmune bullous pemphigoid. | 2.25e-06 | 5 | 17 | 2 | 16920981 | |
| Pubmed | A role for antibody and Fc receptor in the clearance of Brugia malayi microfilariae. | 2.25e-06 | 5 | 17 | 2 | 11920579 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr3p21 | 6.00e-03 | 316 | 17 | 2 | chr3p21 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr1p36 | 2.58e-02 | 681 | 17 | 2 | chr1p36 | |
| GeneFamily | Immunoglobulin like domain containing | 8.18e-03 | 193 | 13 | 2 | 594 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | 1.32e-02 | 718 | 13 | 3 | 28 | |
| Coexpression | CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_UP | 5.93e-06 | 6 | 17 | 2 | M41151 | |
| Coexpression | QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_35DY_UP | 4.14e-05 | 15 | 17 | 2 | M40982 | |
| Coexpression | SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_UP | 1.28e-04 | 26 | 17 | 2 | M41741 | |
| Coexpression | PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_TOP_30_DEG_UP | 1.59e-04 | 29 | 17 | 2 | M40976 | |
| Coexpression | PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGED_POST_VACCINATION_VS_UNCHALLENGED_72HR_TOP_30_DEG_UP | 1.70e-04 | 30 | 17 | 2 | M40975 | |
| Coexpression | GSE25123_WT_VS_PPARG_KO_MACROPHAGE_DN | 2.71e-04 | 199 | 17 | 3 | M7953 | |
| Coexpression | GSE2770_UNTREATED_VS_IL4_TREATED_ACT_CD4_TCELL_48H_UP | 2.75e-04 | 200 | 17 | 3 | M6022 | |
| Coexpression | GSE2770_IL12_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_48H_UP | 2.75e-04 | 200 | 17 | 3 | M6027 | |
| Coexpression | NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_ATIV_UP | 3.04e-04 | 40 | 17 | 2 | M40897 | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.95e-05 | 161 | 17 | 3 | 2849fbc9611af208241b33da3cd18290aafe426b | |
| ToppCell | Adult-Immune-interstitial_macrophage_(C1Q_positive)-D175|Adult / Lineage, Cell type, age group and donor | 4.46e-05 | 185 | 17 | 3 | ab5704b96f1d368911308797d10c7c52766ab134 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c04-COTL1|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.06e-05 | 193 | 17 | 3 | 778fcf8448e81fe18972d97ea8a30ab036d16fe5 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c6-VCAN|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.06e-05 | 193 | 17 | 3 | 52f5b0fbb8ca706206c65e7edbb1ddbd380aebae | |
| ToppCell | Caecum-Macrophage-LYVE1_Macrophage|Caecum / Region, Cell class and subclass | 5.45e-05 | 198 | 17 | 3 | a92c0cacb775aca6bbb302bd9e22c081a112a44d | |
| ToppCell | Bronchial_Brush-Immune-Luminal_Macrophages|Immune / Tissue, Lineage and Cell class of Lung Cells from 10X | 5.45e-05 | 198 | 17 | 3 | 77f41f0e0895b7c732bab1fd2e047f2ed31cbd9d | |
| ToppCell | Caecum-(6)_Macrophage-(61)_LYVE1_Macrophage|Caecum / shred on region, Cell_type, and subtype | 5.45e-05 | 198 | 17 | 3 | e684c3934c163aef4d284b69435832d2c9614f2a | |
| ToppCell | mLN-(4)_Monocyte-(40)_Monocyte|mLN / shred on region, Cell_type, and subtype | 5.54e-05 | 199 | 17 | 3 | bcbb1eee8d79bf670dbe113094c3a292b135ce2f | |
| ToppCell | mLN-(4)_Monocyte|mLN / shred on region, Cell_type, and subtype | 5.54e-05 | 199 | 17 | 3 | 6795ff31f92580195c9db776951f99d647484d24 | |
| ToppCell | mLN-Monocyte|mLN / Region, Cell class and subclass | 5.54e-05 | 199 | 17 | 3 | 241f790cd5d8a9b2451333deecc826a673bae70a | |
| ToppCell | mLN-Monocyte-Monocyte|mLN / Region, Cell class and subclass | 5.54e-05 | 199 | 17 | 3 | dcee372774c169a3048bdaed3734b3215bf8ffad | |
| ToppCell | LPS_only-Hematopoietic_Myeloid-Granulocytic_cells-Mast-cells|LPS_only / Treatment groups by lineage, cell group, cell type | 5.62e-05 | 200 | 17 | 3 | afbbfe0b8e66df36c244935182cb26feeb31a085 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic-Neutrophil-Neu_c2-CXCR4(low)|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.13e-03 | 132 | 17 | 2 | a1fda8c5287168c4f159203ed27cadfb4ce1b131 | |
| ToppCell | PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.21e-03 | 137 | 17 | 2 | 12caa8ed7cc9e7a0f78c14ad5efe2fc28c3ce9be | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Myeloid-Granulocytic-Neutrophil-Neu_c6-FGF23|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.29e-03 | 141 | 17 | 2 | 2d2c468783730d81e3cacb0336027ba0ce1e5f4f | |
| ToppCell | COVID-19_Severe-dn_T|COVID-19_Severe / Disease condition and Cell class | 1.30e-03 | 142 | 17 | 2 | 2008033881b9e1b20926c3508d6ebdb6f1a1528f | |
| ToppCell | PBMC-Control-Myeloid-Classical_Monocyte-Classical_Monocyte-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.32e-03 | 143 | 17 | 2 | 4c5a5db46beb8f2f3c40e8ed95911fbfea61bae0 | |
| ToppCell | Tracheal-NucSeq-Immune_Myeloid-Macrophage_other-Macro_interstitial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.36e-03 | 145 | 17 | 2 | 778655fffd73df101e656154a41b478a1b695116 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Myeloid-Macrophage-macrophage,_alveolar-Macro_c2-CCL3L1|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.38e-03 | 146 | 17 | 2 | 1e81ad3d6d5d5ad2f0176d2a9593a954d38fa294 | |
| ToppCell | TCGA-Breast|World / Sample_Type by Project: Shred V9 | 1.45e-03 | 150 | 17 | 2 | 08686ba1acac5c58667bf62e2af84c691d6bbdfb | |
| ToppCell | 10x5'-GI_large-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_large-bowel / Manually curated celltypes from each tissue | 1.49e-03 | 152 | 17 | 2 | 95944864ce7539ff8de028f5700694931338f3ff | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Macrophage-macrophage,_alveolar-Macro_c2-CCL3L1|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.59e-03 | 157 | 17 | 2 | a98d06cef80bfe8481b0940abce2b29675e45812 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.61e-03 | 158 | 17 | 2 | e7db0ee4740e3c7a4d97d7cd7462e2c2ab458a4b | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.61e-03 | 158 | 17 | 2 | d39e020c3e77eb9d3de600a171d22f94357061d4 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-D-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.63e-03 | 159 | 17 | 2 | 299e2162a82e31196d7f3a110c2db622349edfff | |
| ToppCell | 356C-Fibroblasts-Fibroblast-D|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.63e-03 | 159 | 17 | 2 | 0a3a363b30a8c741e1a3e2525725108d03c21776 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c5-GSTP1(high)OASL(low)|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.71e-03 | 163 | 17 | 2 | d005115aa1e1458b51de7eb719794617a4168608 | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Pvalb-Pvalb_Tpbg|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.73e-03 | 164 | 17 | 2 | f0499e6c1b17c4df72b18b294e3b53ef723da2ac | |
| ToppCell | facs-Marrow-Granulocytes-24m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.75e-03 | 165 | 17 | 2 | 11227bff52eed30b80937fdb1968d0b8e6d30365 | |
| ToppCell | facs-Marrow-Granulocytes-24m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.75e-03 | 165 | 17 | 2 | 036f9749048e5e50769cc3210339bf4da469215d | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Macrophage|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.77e-03 | 166 | 17 | 2 | 2a04915d534a83e65aa168435d6856125b5bdd78 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Macrophage-macrophage,_alveolar|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.77e-03 | 166 | 17 | 2 | 28a44448a0b0d72459e8fe84ce5d666f16f514b3 | |
| ToppCell | normal_Lymph_Node-Myeloid_cells-Pleural_Mac|Myeloid_cells / Location, Cell class and cell subclass | 1.80e-03 | 167 | 17 | 2 | 820472887f43b42ae7e44513ca3d5465fb4f71a7 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_5|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 1.82e-03 | 168 | 17 | 2 | d7d19c93d1c3dd994e18e28d5f36ae7773ff5d7f | |
| ToppCell | 3'_v3-bone_marrow-Myeloid_Mac-Intermediate_macrophages|bone_marrow / Manually curated celltypes from each tissue | 1.82e-03 | 168 | 17 | 2 | 8ade4d098aeecda2d80c1cad1cebe9a063eae948 | |
| ToppCell | PND10-Immune-Immune_Myeloid-Monocytic-Macrophage-iMON-iMON_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.82e-03 | 168 | 17 | 2 | c3d2d573f21350a4a674faff30b06ff644d00ac3 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_5|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.84e-03 | 169 | 17 | 2 | d2def7229fe9d6b0c70cfed349ede491c8c137a0 | |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Hematologic-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.84e-03 | 169 | 17 | 2 | 4e1322cc5e1733e9fb19e08f739a30206f43cea8 | |
| ToppCell | 390C-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)|390C / Donor, Lineage, Cell class and subclass (all cells) | 1.84e-03 | 169 | 17 | 2 | 2c851b2703c7b8b656026f996f5fc027e4a79b36 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Monocytic-Classical_Monocyte-Mono_c2-CD14-HLA-DPB1|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.84e-03 | 169 | 17 | 2 | d4bd489ebdb86e70ed5e3dbbe8518c6cae2197e5 | |
| ToppCell | facs-Marrow-B-cells-18m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.86e-03 | 170 | 17 | 2 | 18cd941bf3ca7cc0b6af1317bd2619d283353de0 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.86e-03 | 170 | 17 | 2 | ff68600b945b3a5437b14e5411b3db800d0ccbe5 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.86e-03 | 170 | 17 | 2 | a78d9789c3e7c84a36e1bd380192d7aba4a4d443 | |
| ToppCell | facs-Marrow-B-cells-18m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.86e-03 | 170 | 17 | 2 | 6e82e41acd1299aa549a32ac036b39754abdf376 | |
| ToppCell | wk_15-18-Hematologic-Myeloid-GMP|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.88e-03 | 171 | 17 | 2 | 4b8b67c289898ae114a07a2147b5a6f8ec9dd308 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-monocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.88e-03 | 171 | 17 | 2 | 992df143d76f9e7fb1997a8996f61e941f0f9d4f | |
| ToppCell | ILEUM-non-inflamed-(3)_MNP-(3)_mature_DC|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 1.88e-03 | 171 | 17 | 2 | 341f9f79c1ed654ab347e25dc4936f89ffdf9617 | |
| ToppCell | facs-BAT-Fat-18m-Myeloid-nan|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.90e-03 | 172 | 17 | 2 | 36fe66a8c0aecee7a19269be23210c0ed7abb155 | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Hematopoietic-Myeloid-CLC+_Mast_cell|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.92e-03 | 173 | 17 | 2 | b9dc42d629d13e63aada5ae49ba0cbb0952c5fe9 | |
| ToppCell | tumor_Lymph_Node_/_Brain-Myeloid_cells-Alveolar_Mac|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 1.92e-03 | 173 | 17 | 2 | 4efa0878ed1ede8fa5d6c191a76d4f70558ba761 | |
| ToppCell | normal_Lymph_Node-Myeloid_cells-CD163+CD14+_DCs|normal_Lymph_Node / Location, Cell class and cell subclass | 1.92e-03 | 173 | 17 | 2 | 38f88f5bbf92a3bf5109bc4782cd071b7cb1ca34 | |
| ToppCell | droplet-Marrow-BM-30m-Myeloid-monocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.95e-03 | 174 | 17 | 2 | 118ba2729ecc6aa1bb8548f3cf537b3f9e902ef0 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Macrophage-macrophage,_alveolar-Macro_c6-VCAN|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.95e-03 | 174 | 17 | 2 | eaaf17a06efc09ed4752b449827b1f0f424d3dad | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.97e-03 | 175 | 17 | 2 | 69b59ec58e64644deb7e07f31ef495ef4a6f6276 | |
| ToppCell | LPS-IL1RA-Hematopoietic_Meg-Ery-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.97e-03 | 175 | 17 | 2 | 4d36da7399c62c170cb603957b35a35efb2c3fbe | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.97e-03 | 175 | 17 | 2 | 4f7498b5a0ed52c348a5f94bcd41d830ba7954ea | |
| ToppCell | LPS-IL1RA-Hematopoietic_Meg-Ery-Erythroid-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.97e-03 | 175 | 17 | 2 | e4c9b3c6bde390a3892b112b673f93e118220eb9 | |
| ToppCell | LPS-IL1RA-Hematopoietic_Meg-Ery|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.97e-03 | 175 | 17 | 2 | 2c39c1b112e873403ad2add8595cc256bf0b97a6 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2-Transitional_Club-AT2_L.0.4.1.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.97e-03 | 175 | 17 | 2 | dbd9dac129fb6ae5f55e7b96d04b37585458dc4a | |
| ToppCell | Bronchial_Biopsy-Immune-Luminal_Macrophages|Bronchial_Biopsy / Tissue, Lineage and Cell class of Lung Cells from 10X | 1.97e-03 | 175 | 17 | 2 | 1cf99de391552d4f8dbe2ed5b01fc3b8adca61b6 | |
| ToppCell | droplet-Marrow-nan-24m-Myeloid-monocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.99e-03 | 176 | 17 | 2 | eddac2ba68d234e3f56f4ca0e11c19bc0e95b6e1 | |
| ToppCell | droplet-Marrow-nan-21m-Myeloid-monocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.01e-03 | 177 | 17 | 2 | b860013f1fd397400a62d66ab521cfc81349ffe2 | |
| ToppCell | LPS-antiTNF-Hematopoietic_Meg-Ery-Erythroid-Erythroid|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.04e-03 | 178 | 17 | 2 | 370749834a11d981e9ede26d5f63f0ecb551c015 | |
| ToppCell | LPS-antiTNF-Hematopoietic_Meg-Ery-Erythroid|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.04e-03 | 178 | 17 | 2 | eafacc8cd3e986d6ca309e05b6e241331a584fa5 | |
| ToppCell | LPS-antiTNF-Hematopoietic_Meg-Ery|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.04e-03 | 178 | 17 | 2 | 6a5c31e976852edc7d9e899da8e2a1bf23d36759 | |
| ToppCell | LPS-IL1RA+antiTNF-Hematopoietic_Meg-Ery|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.06e-03 | 179 | 17 | 2 | 7329b45376a9e9a4fe34d4aa0b33af6dda0a8e3b | |
| ToppCell | LPS-IL1RA+antiTNF-Hematopoietic_Meg-Ery-Erythroid|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.06e-03 | 179 | 17 | 2 | 6e4740f99f66d3e9348fa5057cf1030454819aa8 | |
| ToppCell | LPS-IL1RA+antiTNF-Hematopoietic_Meg-Ery-Erythroid-Erythroid|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.06e-03 | 179 | 17 | 2 | ee60ac43fb62c09967a26bbcf9306ac5ea2bdc1e | |
| ToppCell | metastatic_Brain-Myeloid_cells-Pleural_Mac|metastatic_Brain / Location, Cell class and cell subclass | 2.08e-03 | 180 | 17 | 2 | 7de1c8ab1152fa517c6b4830d93ff53a19fca3d7 | |
| ToppCell | normal_Lymph_Node-Myeloid_cells-Pleural_Mac|normal_Lymph_Node / Location, Cell class and cell subclass | 2.10e-03 | 181 | 17 | 2 | 921e917f83105896ad8918dc134b871708024021 | |
| ToppCell | PCW_05-06-Hematologic_Myeloid-Hem_Myeloid_monocytic-im_monocyte_(14)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.10e-03 | 181 | 17 | 2 | 3457c1d431db4282be5a6243119e48960748ede7 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Granulocytic-Neutrophil-Neu_c6-FGF23|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.13e-03 | 182 | 17 | 2 | f9c013075477e77a8373c73301a51e7e3f35369c | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-papillary_tips_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.13e-03 | 182 | 17 | 2 | 678eadd57e7e830fc2bf9fd35616d3badce01705 | |
| ToppCell | NS-moderate-d_07-13-Myeloid-Monocyte-derived_Macrophage|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.13e-03 | 182 | 17 | 2 | e03e995e5fd14fc6a7559b83c0ca4e7ccc8e3d0f | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-papillary_tips_cell-Papillary_Tip_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.13e-03 | 182 | 17 | 2 | 8d1229fa5aa6e2e38f2ac6fe4f4dc89752fe9344 | |
| ToppCell | cellseq2-Immune-Hematopoietic-Granulocytic-Neutrophil|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.13e-03 | 182 | 17 | 2 | 1932d77491d6d46278f01fd70eb469ef1b356619 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.0.5.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.15e-03 | 183 | 17 | 2 | 103c4c4595d8daa677679fd2fa1e99cd398e56dd | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Principal_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.15e-03 | 183 | 17 | 2 | d340ab5a77e8d819a1dfb4ca3e9a4b9bc988923c | |
| ToppCell | 367C-Fibroblasts-Fibroblast-D|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 2.15e-03 | 183 | 17 | 2 | 19cc0009f5332b6e4d4274df123eebbfc80b669a | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.15e-03 | 183 | 17 | 2 | 3c516fe5083f02bad1f464ed284010b4131a833c | |
| ToppCell | cellseq2-Immune-Hematopoietic|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.15e-03 | 183 | 17 | 2 | 324ec4374b552da7ce03809945b3a0798342d4ba | |
| ToppCell | cellseq2-Immune-Hematopoietic-Granulocytic|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.15e-03 | 183 | 17 | 2 | cfbf8539104cef9ca830ad4f6bb278746f7078f7 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Granulocytic-Neutrophil|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.15e-03 | 183 | 17 | 2 | 75da8c05b6d636f434c5684e0166fed0de3547b4 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.15e-03 | 183 | 17 | 2 | 9c2689d76fc6d30f5ab093428aa669d0a98953cf | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Granulocytic|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.15e-03 | 183 | 17 | 2 | 340621a8e720bd98da335f90598096833681834c | |
| ToppCell | 367C-Fibroblasts-Fibroblast-D-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 2.15e-03 | 183 | 17 | 2 | b12b89debc9dd6396188bc8fe44f54c01c560966 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Non-neuronal-Endothelial_Myeloid-Micro|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.17e-03 | 184 | 17 | 2 | 371c1927ac06b77ff462a94cca6acb802f9724ff | |
| ToppCell | PBMC-Control-Myeloid-Neutrophil-immature_Neutrophil|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.17e-03 | 184 | 17 | 2 | a8c6028d745aaa6ee7842259238694cb50ce0526 | |
| ToppCell | PBMC-Control-Myeloid-Neutrophil-immature_Neutrophil-Neu_4|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.17e-03 | 184 | 17 | 2 | 081d045f3bc98a36f342de7d50f39c9a888dd7eb | |
| ToppCell | Control-Myeloid_G-immature_Neutrophil|Control / Disease group, lineage and cell class | 2.17e-03 | 184 | 17 | 2 | 45f873236f7e90fb78c8e291d3b5b92d121acec9 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.17e-03 | 184 | 17 | 2 | 7294b379ce4cb8fa75e432559082f93cd106aaf5 | |
| ToppCell | PBMC-Control-Myeloid-Neutrophil-immature_Neutrophil|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.17e-03 | 184 | 17 | 2 | 84c20730cd92b9aaa50077d7b625e37e7f9e91d2 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Non-neuronal-Endothelial_Myeloid-Micro-Microglia|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.17e-03 | 184 | 17 | 2 | dd6777a0cb49cd79fc439920c3c930a1e4681bb0 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Non-neuronal-Endothelial_Myeloid-Micro-Microglia-Micro_L1-6_C1QC|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.17e-03 | 184 | 17 | 2 | fbac70333e4f028bfbdd9cc9401427caac9f0c47 | |
| ToppCell | PBMC-Control-Myeloid-Neutrophil-immature_Neutrophil-Neu_4|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.17e-03 | 184 | 17 | 2 | d31d4116d1d196633784863781fa45673607a421 | |
| ToppCell | PBMC-Mild-cDC_9|Mild / Compartment, Disease Groups and Clusters | 2.17e-03 | 184 | 17 | 2 | 2e0c9a2c40c892a2d435eafb31f1f838de9baf15 | |
| ToppCell | CV-Moderate-7|Moderate / Virus stimulation, Condition and Cluster | 2.20e-03 | 185 | 17 | 2 | a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f | |
| ToppCell | droplet-Liver-Hepatocytes-21m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.20e-03 | 185 | 17 | 2 | 60206c7322b4ddb2010040aac70561df842c9843 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Non-neuronal-Endothelial_Myeloid|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.20e-03 | 185 | 17 | 2 | 6b832b3e080dfadd21253ac45022192f4d3cb37b | |
| ToppCell | PCW_05-06-Hematologic_Myeloid-Hem_Myeloid_monocytic-im_myeloid_progenitor3_(13)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.22e-03 | 186 | 17 | 2 | 6575ec6a626cdea169ffd185d47828dfaa29475d | |
| Disease | retinal degeneration (biomarker_via_orthology) | 1.03e-04 | 28 | 16 | 2 | DOID:8466 (biomarker_via_orthology) | |
| Disease | granulocyte percentage of myeloid white cells | 3.80e-04 | 268 | 16 | 3 | EFO_0007997 | |
| Disease | eosinophil measurement | 1.54e-03 | 108 | 16 | 2 | EFO_0803540 | |
| Disease | breast carcinoma | 1.85e-03 | 1019 | 16 | 4 | EFO_0000305 | |
| Disease | facial morphology measurement | 1.88e-03 | 466 | 16 | 3 | EFO_0007841 | |
| Disease | photoreceptor cell layer thickness measurement | 2.86e-03 | 148 | 16 | 2 | EFO_0803370 | |
| Disease | autoimmune disease | 3.89e-03 | 173 | 16 | 2 | EFO_0005140 | |
| Disease | monocyte count | 4.71e-03 | 1320 | 16 | 4 | EFO_0005091 | |
| Disease | diastolic blood pressure, systolic blood pressure | 5.23e-03 | 670 | 16 | 3 | EFO_0006335, EFO_0006336 | |
| Disease | Thyroid preparation use measurement | 6.04e-03 | 217 | 16 | 2 | EFO_0009933 | |
| Disease | monocyte percentage of leukocytes | 6.66e-03 | 731 | 16 | 3 | EFO_0007989 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GCHLNGKSTHYHCMQ | 541 | Q86V15 | |
| SHNGTYHCSGMGKHR | 161 | Q92637 | |
| CDNGHCMLNGTHGPS | 736 | Q13191 | |
| GMGDSCQIHGGFHSC | 106 | Q96LU7 | |
| GHMPHGGSSNNLCHT | 6 | Q9HC98 | |
| KCECHGHTHSCHFDM | 346 | P55268 | |
| GDSHHSHAGGHCGGC | 221 | Q86UY6 | |
| HSMHQALCPGHTGLC | 416 | O15303 | |
| RAAMACSHQRCHGHG | 351 | O43820 | |
| SHNGTYHCSGMGKHR | 161 | P12314 | |
| QHCHYCGGSGMETIN | 251 | Q96EY1 | |
| ALHMSCHGDSGPFQC | 1231 | Q9UHF7 | |
| MSHGHSHGGGGCRCA | 1 | Q9GZP4 | |
| NFCLTCGHGGHTSHM | 936 | Q6PJI9 | |
| MCCHGRQGTVHIHTS | 76 | Q71RG6 | |
| HGGKSHYSCGGCMKH | 206 | Q9H707 | |
| AVCNHHGTMQGGHYT | 711 | Q70CQ4 | |
| CGTHTSSCGHIMHAH | 1161 | Q8IWV8 |